Salvage temozolomide for prior temozolomide responders

Temozolomide (TMZ) often is used as adjuvant or first‐line therapy for patients with glioma. Because of potential hematologic complications, it usually is discontinued after 12–18 cycles, even in responders. Subsequent salvage therapies are reported to have limited efficacy at the time of disease recurrence. In the current study, the authors assessed the outcome and complications of reusing TMZ at the time of disease recurrence in patients who previously responded to treatment.